Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL).

Trial Profile

Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Ofatumumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2019.
    • 08 Apr 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov.
    • 05 Jan 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top